Abstract. Development of multidrug resistance (MDR) remains a major hurdle to successful cancer chemotherapy and MDR1/P-gp overexpression is believed to be mainly responsible for MDR of tumor cells. Twist1, which is a highly conserved transcription factor that belongs to the family of basic helix-loop-helix proteins, has been shown to be a major regulator of the epithelial-mesenchymal transition (EMT), and therefore promotes carcinoma metastasis. Recently, a novel function of Twist1 was reported to confer radioresistance or chemoresistance in cervical cancer. However, mechanisms of such efficacy are not completely elucidated. In the present study, we firstly analyzed the relationship between Twist1 and MDR1/P-gp expression in human cervical cancer specimens and demonstrated a positive correlation between Twist1 and MDR1/P-gp expression in the same patient. Additionally, we provide the first evidence that silencing of Twist1 by RNAi downregulated MDR1/P-gp expression in HeLa cervical cancer cells, suppressed the cell proliferation, inhibited Rhodamine123 efflux activity of cells and sensitized cells to cisplatin treatment. Collectively, these findings suggest that Twist1-mediated modulation of MDR1/P-gp expression plays an important role in sensitization of cervical cancer cells to cisplatin, and also indicate a novel therapeutic strategy to overcome drug resistance through inactivation of Twist1 expression in cervical cancer.

Introduction
Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause of cancer-related death in females worldwide, accounting for 9% (529,800) of the total new cancer cases and 8% (275,100) of the total cancer deaths among females in 2008 (1). Surgery, alone or combined with radiotherapy has long been the cornerstone in the treatment of cervical cancer (2,3). Unfortunately, not all patients respond to such treatment, leading to an extremely low survival rate for advanced stage. To increase survival rates, different strategies with neoadjuvant chemotherapy have been developed (4,5). Additionally, cisplatin-based chemotherapy has traditionally been reserved as part of treatment for metastatic or recurrent cervical cancer disease (6). However, resistance of cervical cancer cells to antineoplastic agents is the major reason why chemotherapy-based treatment modalities of malignant tumors may fail (7,8). Therefore, exploring a novel approach to improve drug sensitivity appeared to be urgently needed.

Accumulating evidence has demonstrated that cervical cancer cells can exhibit a cross-resistant phenotype against several unrelated drugs that differ widely with respect to molecular structure and target specificity (9,10). This phenomenon has been termed multidrug resistance (MDR). MDR has most often been linked to overexpression of MDR1/P-gp, which is overexpressed in many drug-resistant cell lines and in cervical cancer (11). MDR1/P-gp functions as a xenobiotics pump transporting a variety of toxic agents including anticancer drugs from the intracellular milieu to the outside of the cell (12,13). In view of the vital role of MDR1/P-gp in the treatment of cancer, prevention of MDR1/P-gp induction in cancer cells may help to avert drug resistance.

Twist1, a basic helix-loop-helix transcription factor, has been known to contribute to tumor metastasis by promoting an epithelial-mesenchymal transition (EMT), which is a process initially observed in embryonic development in which cells lose epithelial characteristics and gain mesenchymal properties to increase motility and invasion (14,15). Recently, a bulk of evidence has demonstrated a close link between EMT and
insensitivity to several growth factors or chemotherapeutic agents (16,17). A novel function of Twist1 has been reported in the development of acquired chemoresistance in human cancer cells. Upregulation of Twist1 was associated with cellular resistance to microtubule-targeting anticancer drugs in various types of cancers (18-20). In addition, overexpression of Twist1 confers radioresistance or chemoresistance of cervical cancers, thereby leading to a poorer prognosis (21). Therefore, targeting Twist1 could be a novel therapeutic approach for the treatment of cervical cancer by overcoming drug resistance.

These above observations prompted us to examine whether Twist1 acts as a potential regulator of MDR1/P-gp. Therefore, the purpose of this study was to investigate the relationship of Twist1 and MDR1/P-gp in cervical cancer and to explore whether Twist1 played an important role in drug resistance of cervical cancer cells by regulating MDR1/P-gp. To the best of our knowledge, this is the first report to describe that the expression of MDR1/P-gp was significantly positively associated with Twist1 expression in clinical cervical cancer tissues and that Twist1 silencing not only downregulated MDR1/P-gp expression but also enhanced chemosensitivity of human cervical cancer HeLa cells to cisplatin.

Materials and methods

**Cell line and tissue specimens.** The human cervical cancer HeLa cell line (obtained from ATCC) was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C in a 5% CO₂ atmosphere. Forty-two human cervical cancer (including 26 squamous cell carcinoma and 16 adenocarcinoma) tissue specimens were obtained from patients who underwent surgical resection with the approval of the Institutional Review Board (IRB) of the First Affiliated Hospital of Medical College of Xi'an Jiaotong University.

**Immunohistochemistry (IHC).** IHC was conducted using a Dako Autostainer Plus system (Dako Corp., Carpinteria, CA) according to the manufacturer's protocol. Formalin-fixed, paraffin-embedded cervical tissues were cut at a thickness of 4 µm, then were deparaffinized, rehydrated and subjected to 5-min pressure-cooking antigen retrieval in citrate buffer (10 mM, pH 6.0), 10 min double endogenous enzyme block, 60 min mouse anti-Twist1 (Abcam, 1:50) or mouse anti-MDR1/P-gp (Santa Cruz Biotechnology, 1:100) primary antibody incubation and 30-min incubation with DakoCytofration EnVision HRP reagent for mouse antibodies. Signals were detected by adding the substrate hydrogen peroxide using diaminobenzidine (DAB) as a chromogen and peroxide using diaminobenzidine (DAB) as a chromogen. A case was diagnosed as positive when Twist1 staining in the nuclei and cytoplasm were analyzed by two histopathologists. A case was diagnosed as positive when Twist1 staining in the nuclei and cytoplasm were analyzed by two histopathologists. A case was diagnosed as positive when Twist1 staining in the nuclei and cytoplasm were analyzed by two histopathologists.

**Reverse transcription-polymerase chain reaction (RT-PCR).** After shRNA transfection, total RNA was isolated using the RNAfast200 Total RNA Extract kit (Fastagene, China). The mRNA pGPU6/GFP/Neo-Twist1 (sh-Twist1) (F: 5'-CACCG GTACATCGACTCTTACTCTTTAAGAGGTTAGAGG AAGTCGAGTACCTTTTGG-3'; R: 5'-GATCCAAAAA GGTACATCGACTCTTACTCTTTAAGAGGTTAGAGG AAAGTCGAGTACCTTTTGG-3'; target sequence: 5'-GCTACATC GACTTCTTACC-3') and pGPU6/GFP/Neo vectors containing negative control shRNA (sh-NC) were purchased from Shanghai GenePharma Co. (Shanghai, China). For transient transfection, HeLa cells were seeded in 6-well plates at the density of 5x10⁴ cells/well and incubated at 37°C in an atmosphere with 5% CO₂ for 12 h. For each well, 7 µl of Eugene HD Transfection Reagent (Roche) and 2 µg of sh-Twist1 or sh-NC mixture were diluted into 100 µl of DMEM culture medium without serum and incubated for 20 min. Subsequently, the mixture was added to the cells. Six hours later, the medium was replaced with 2 ml of fresh DMEM medium containing 10% FBS, and subsequent experiments were performed after culturing for another 24 h. For stable transfection, cells were cultured in DMEM culture medium for 48 h after transfection as above, and then cells were grown in 10-cm cell plates with medium containing 300 µg/ml G418 (Invitrogen). After 3 weeks of culture, visible colonies were picked up and expanded. The stably transducted clones of HeLa cells (HeLa/sh-Twist1 and HeLa/sh-NC) were observed to show green fluorescence under microscope. Western blotting was used to identify the positive clone.

**Cell viability assay.** Cell viability and IC₅₀ values (drug concentration causing 50% inhibition of cell growth) were analyzed by the methyl tetrazolium (MTT) assay. For transient transfection, cells were seeded at 5x10⁴ cells/well in 96-well plates one day before transfection, then the MTT assay was performed just before transfection as well as at 24, 48 and 72 h after transfection. For stably transducted clones, cisplatin at various concentrations (from 0 to 50 µM) was added to each 96-well plate and the MTT assay was performed at 48 and 72 h after intervention. For the assay, 20 µl of 5 mg/ml MTT (Invitrogen) was added to each well, then the cells were incubated for 4 h before 180 µl dimethylsulphoxide (DMSO, Sigma) was added. After the insoluble crystals were completely dissolved, the absorbance of each well was measured at 490 nm using a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA).

**Apoptosis assay.** HeLa cells were harvested 48 h after sh-Twist1 or sh-NC transfection and resuspended in binding buffer (100 µl/500,000 cells: 140 mmol/l NaCl, 5 mmol/l CaCl₂, and 10 mmol/l HEPES buffer) followed by 3 washed with phosphate-buffered saline (PBS, pH 7.4). Annexin-V-FITC (5 µl) and 10 µl propidium iodide (PI, 1 µg/ml) were added and then the cell suspension was incubated in a dark chamber at room temperature for 10 min. After centrifugation, the cell pellet was resuspended in 200 µl binding buffer and subjected to FACS analysis using the FACSsort flow cytometer (BD Biosciences). The percentage of apoptotic and necrotic cells was determined using FCS express software (DeNovo Software, Los Angeles, CA).
RNA (2 µg) was reverse transcribed using the RevertAid™ First Strand cDNA Synthesis kit (MBI Fermentas, Germany) according to the manufacturer's instructions. All PCR analyses were subsequently performed with 1 µg of the cDNA reaction utilizing conditions as follows: 94°C, 5 min; 32 cycles of 94°C, 30 sec; 58°C, 30 sec; 72°C, 45 sec. Reactions were terminated with 72°C, 7-min extension. Primers used were F: 5'-CGTTTC CAGGGAGCTGCGG-3' and R: 5'-GCCGAAGCTGCGGA GCTTGCA-3' for Twist1 and for β-actin F: 5'-GGG GCCGACC ACCATGTAACC-3' and R: 5'-AGGGGGCCGACTCGT CATACT-3'. PCR products were analyzed by 2% agarose gel electrophoresis and visualized using ethidium bromide staining.

Western blotting. After the transfection, cells were lysed in ice-cold RIPA lysis buffer (1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 150 mmol/l NaCl and 10 mmol/l Tris-HCl) containing a protease inhibitor cocktail. A total of 30 µg of protein was separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. After being blocked in Tris-buffered saline (TBS) containing 5% skim milk at room temperature for 1 h, the membranes were incubated with mouse monoclonal Twist1 antibody (Abcam, 1:200) or mouse monoclonal MDR1 antibody (Santa Cruz Biotechnology, 1:250) at 4°C for 12 h, and then with horseradish peroxidase (HRP)-conjugated anti-mouse antibody (Zhongshan, China) at a dilution of 1:3,000 at room temperature for 1 h. Signals were detected on X-ray film using the ECL detection system (Pierce, Rockford, IL, USA). Loading differences were normalized using a monoclonal GAPDH antibody.

Immunofluorescence staining. HeLa/sh-NC and HeLa/sh-Twist1 cells were cultured on glass coverslips for 24 h. The cells were washed with PBS and fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.1% Triton X-100 and blocked with 3% bovin serum albumin (BSA) for 1 h. Coverslips were incubated with Twist1 or MDR1/P-gp primary antibodies described above (dilution rate for both antibodies used were 1:100) at 4°C overnight and then with TRITC or FITC labeled secondary IgG conjugates (Zhongshan, China). After 4,6-diamidino-2-phenylindole (DAPI, 1 µg/ml, Sigma) counterstaining for nuclei, fluorescence was visualized by fluorescence microscopy (Olympus Optical Co., Ltd., Tokyo, Japan).

Detection of MDR1/P-gp function. Efflux of rhodamine 123 (Rh123) was chosen to detect the MDR1/P-gp function of cells. HeLa/sh-NC and HeLa/sh-Twist1 cells were cultured in 6-well plates, and when the cells reached 70-80% confluence, Rh123 (Sigma) was added to the cells at a final concentration of 0.25 µg/ml and incubated at 37°C for 1 h. Cells were washed 3 times with 4°C PBS and resuspended at 5-10x10^5 cells/ml in 4°C PBS. Rh123 fluorescence was analyzed with a FACStar flow cytometer (BD Biosciences) equipped with an argon laser. The blast population was gated by forward and side scatter characteristics. Rh123 fluorescence of 10,000 cells was measured logarithmically through a 530 nm bandpass filter at an excitation wavelength of 488 nm. HeLa cells without incubation with Rh123 served as a negative control. Rh123 efflux was measured by counting cells in the M1 region of the plot and calculated as the percentage of cells in the M1 region of the plot. The higher the percentage of cells in the M1 region the greater the cellular Rh123 efflux and also the greater the MDR1/P-gp function.

Statistical analysis. All statistical analyses were performed using SPSS 16 (SPSS Inc., Chicago, IL). Statistical significance of differences among the control and various treatment groups were compared by one-way ANOVA, followed by the Dunnett's t-test for separate comparisons. The expression of Twist1 and MDR1/P-gp were compared using the Pearson's test. P<0.05 was considered statistically significant.

Results

Expression of Twist1 and MDR1/P-gp in clinical cervical carcinoma tissues. Immunohistochemical staining showed strong cytoplasmic and/or nuclear staining for Twist1, cytoplasmic and/or membrane staining for MDR1/P-gp in both cervical squamous cell carcinoma and adenocarcinoma tissues (Fig. 1). According to the total 42 tissue specimens, the positive expression of Twist1 and MDR1/P-gp was 31/42 (73.8%) and 27/42 (64.3%), respectively. Of the 31 Twist1-positive specimens, 24 (77.4%) showed positive staining of MDR1/P-gp. Additionally, of the 11 Twist1-negative specimens, 8 (72.7%) were MDR1/P-gp negative. The Spearman analysis showed that the expression level of MDR1/P-gp was significantly positively associated with Twist1 expression (R=0.460, P=0.008; Table I).

Detection of MDR1/P-gp function. Efflux of rhodamine 123 (Rh123) was chosen to detect the MDR1/P-gp function of cells. HeLa/sh-NC and HeLa/sh-Twist1 cells were cultured in 6-well plates, and when the cells reached 70-80% confluence, Rh123 (Sigma) was added to the cells at a final concentration of 0.25 µg/ml and incubated at 37°C for 1 h. Cells were washed 3 times with 4°C PBS and resuspended at 5-10x10^5 cells/ml in 4°C PBS. Rh123 fluorescence was analyzed with a FACStar flow cytometer (BD Biosciences) equipped with an argon laser. The blast population was gated by forward and side scatter characteristics. Rh123 fluorescence of 10,000 cells was measured logarithmically through a 530 nm bandpass filter at an excitation wavelength of 488 nm. HeLa cells without incubation with Rh123 served as a negative control. Rh123 efflux was measured by counting cells in the M1 region of the plot and calculated as the percentage of cells in the M1 region of the plot. The higher the percentage of cells in the M1 region the greater the cellular Rh123 efflux and also the greater the MDR1/P-gp function.

shRNA silencing of Twist1 at the mRNA and protein levels. HeLa cells, which have a high level of Twist1 expression, were transiently transfected with 1 µg/ml sh-Twist1 or sh-NC. Total RNA and protein were isolated and analyzed by RT-PCR and western blotting at 48 h after transfection. Compared with the Blank (no shRNA) and sh-NC transfected cells, the expression of Twist1 was obviously suppressed in cells transfected with sh-Twist1 at both the mRNA and protein levels (Fig. 2).

Downregulation of Twist1 inhibits growth and promotes apoptosis of HeLa cells. The role of Twist1 in the growth of HeLa cells was determined by MTT assay. As shown in Fig. 3A, downregulation of Twist1 by transient transfection of sh-Twist1 in HeLa cells caused significant inhibition of cell proliferation compared with the Blank and sh-NC transfected cells (P<0.05). The proliferation rate of HeLa cells transfected
with 1 µg/ml sh-Twist1 was 0.88±0.032, 0.71±0.046 and 0.58±0.039 for 24, 48 and 72 h, respectively, which indicated a time-dependent growth inhibition effect.

Since we observed the inhibitory effects of Twist1 silencing on the growth of HeLa cells, we next examined the effects of Twist1 silencing on the apoptosis of HeLa cells.
using Annexin-V and PI double staining. The effects of Twist1 silencing on the apoptosis of HeLa cells, as measured by flow cytometry, are shown in Fig. 3B and C. sh-Twist1 resulted in 48.14% of apoptotic cells, while the baseline of the control cells (Blank) was 12.86% (P<0.05). These results indicate that downregulation of Twist1 inhibited growth and promoted apoptosis in HeLa cells.

Silencing of Twist1 represses MDR1/P-gp expression. To further investigate the relationship between Twist1 and MDR1/P-gp in cervical cancer, stable Twist1 knockdown (HeLa/sh-Twist1) and control (HeLa/sh-NC) HeLa cells were generated. The protein expression of Twist1 and MDR1/P-gp were then investigated by western blotting. As shown in Fig. 4A and B, Twist1 ablation in HeLa/sh-Twist1 cells accompanied with a significant repression on MDR1/P-gp expression was observed. Immunofluorescence staining confirmed these findings (Fig. 4C).

Silencing Twist1 abates MDR1/P-gp function. Since MDR1/P-gp was downregulated by Twist1 ablation, we next examined the effects of silencing Twist1 on MDR1/P-gp function. Rh123 efflux is sensitive and specific for indicating the transport function of MDR1/P-gp. MDR1/P-gp-mediated transport indicated by intracellular decrease of Rh123 fluorescence was studied using flow cytometry. Compared with HeLa/sh-NC cells, a significant increase of intracellular Rh123 was observed in HeLa/sh-Twist1 cells, the mean percentage of Rh123 efflux cells (cells in M1 region) was 26.41% and 7.53% in HeLa/sh-NC cells and HeLa/sh-Twist1 cells, respectively (P<0.05) (Fig. 5). These results suggest that the repression of MDR1/P-gp expression by silencing Twist1 in HeLa/sh-Twist1 cells results in a great loss of MDR1/P-gp function in drug efflux.

Abated MDR1/P-gp function increases cell sensitivity to cisplatin. To evaluate the biological significance of Twist1 on the cell sensitivity to cisplatin, MTT assay was then performed. Compared with HeLa and HeLa/sh-NC cells, HeLa/sh-Twist1 cells showed a significant decrease in cell viability over 48 and 72 h. Cisplatin (15 µM) induced only a moderate (but significant) decrease in cell viability of HeLa cells and HeLa/sh-NC cells, but this decrease was much more significant in HeLa/sh-Twist1 cells (Fig. 6A). The IC$_{50}$ value to cisplatin for HeLa cells, HeLa/sh-NC cells and HeLa/sh-Twist1 cells was 25.2±2.79, 24.9±1.84, 16.1±1.98 µM and 19.3±2.31, 18.7±1.92, 11.4±2.01 µM for 48 and 72 h, respectively, suggesting the reduced IC$_{50}$ value to cisplatin by Twist1 silencing (Fig. 6B).

Discussion

Recently, a novel function of Twist1 has been reported in the development of acquired chemoresistance in human cancer cells (18-20). However, the reason that Twist1 contributes to drug resistance in the treatment of cervical cancer has not yet been established. In this study, we firstly analyzed the
Figure 5. Effect of Twist1 silencing on MDR1/P-gp activity in HeLa cells. (A) Efflux of Rh123 was chosen to detect the MDR1/P-gp function of HeLa/sh-NC and HeLa/sh-Twist1 cells. Cells were incubated with 0.25 µg/ml Rh123 for 1 h at 37˚C and then Rh123 fluorescence was analyzed by FACStar flow cytometry. Rh123 efflux was measured by counting cells in the M1 region of the plot. The marker bar M1 was set to indicate the cells with high Rh123 efflux and M2 was set to indicate the cells with low Rh123 efflux. (B) Quantitative analysis of the percentage of M1 cells. Three independent experiments were performed and data shown are the mean ±SEM. *P<0.05 vs. parental HeLa cells.

Figure 6. Increased sensitivity to cisplatin in Twist1 silencing HeLa cells. (A) Effect of cisplatin on cell viability. HeLa cells, HeLa/sh-NC cells and HeLa/sh-Twist1 cells were treated with 15 µM cisplatin for 48 and 72 h, respectively, cell viabilities were then determined by the MTT assay. HeLa/sh-Twist1 cells showed a decreased viability in response to cisplatin. (B) IC_{50} values of cisplatin. Cells were treated with various concentrations of cisplatin for 48 and 72 h, and cell growth were also determined by the MTT assay. The IC_{50} values were estimated from growth inhibition curves, showing a significant decrease of IC_{50} for cisplatin in HeLa/sh-Twist1 cells. All of the data shown represent the mean ± SEM of three independent experiments. *P<0.05.
relationship between Twist1 and MDR1/P-gp expression in cervical cancer specimens and demonstrated a positive correlation between Twist1 and MDR1/P-gp expression in the same patient. Additionally, we provided the first evidence that silencing of Twist1 downregulated MDR1/P-gp expression, inhibited its efflux activity, and sensitized cervical cancer cells to cisplatin treatment.

Twist1 is a highly conserved transcription factor that belongs to the family of basic helix-loop-helix proteins, which play a central role in cell type determination and cell differentiation (14,15). Recently, accumulating studies have shown that Twist1 was overexpressed in a variety of solid cancers including breast, prostate and gastric carcinomas rendering Twist1 as a potential oncogene in tumorigenesis (22-24). Twist1 has been found to function as an antiapoptotic factor through both p53-dependent and p53-independent pathways (22). Downregulation of Twist1 through small interfering RNA promotes apoptosis in human breast cancer and melanoma cell lines (25). Consistent with these findings, we also observed that inactivation of Twist1 by RNA interference induced cell apoptosis in cervical cancer HeLa cells though the mechanisms have not been studied.

EMT is a complex process which disaggregates structured epithelial units to enable cell motility and morphogenesis in embryonic development and is critically linked with up-regulated invasion, metastasis and angiogenesis in cancer progression (14,15). In addition, the EMT of cancer cells not only causes increased metastasis, but also contributes to drug resistance (19). Furthermore, it has been reported that drug-resistant MCF-7 cells exhibit EMT gene expression patterns and paclitaxel-resistant epithelial ovarian carcinoma cells lose their epithelial features, acquire mesenchymal characteristics, and increase their capacity for migration and invasion, which are events characteristic of the EMT (16). Twist1 is a major regulator of EMT and it has also been identified as capable of promoting carcinoma metastasis. The elevated Twist1 expression is found to be positively correlated with aggressiveness of cancer and poor survival rate (22,24). Recently, Li et al demonstrated that cells undergoing EMT displayed up-regulation of MDR1/P-gp, MDR to chemotherapeutic agents as well as increased in vitro invasiveness potential (19). Twist1 RNAi largely inhibited EMT induction and partially reversed MDR phenotype (19). However, the relationship between EMT and drug resistance seems complicated. Whether the expression of MDR1/P-gp is regulated by Twist1 remains to be elucidated.

The expression of MDR1/P-gp is regulated at the transcriptional level by multiple signaling pathways (26), including those mediated by hypoxia-inducible factor-1α (HIF-1α), p53, and even chromosomal rearrangement (26-28). MDR1/P-gp expression is also regulated by epigenetic mechanisms, such as methylation and acetylation (29). Post-transcriptional regulation of MDR1/P-gp expression by microRNA has also been reported (30,31). Recently, a potential transcriptional regulatory role of Twist1 has been identified in chemotherapy drug resistance. During generation of acquired resistance to paclitaxel, nasopharyngeal carcinoma cells showed upregulation of Twist1 at both the mRNA and protein levels and were also cross-resistant to vincristine (18). In the present study, our findings indicate a novel role of Twist1 in maintaining the cisplatin-resistant phenotype of cervical cancer HeLa cells through regulating MDR1/P-gp expression. However, further research is needed to define the molecular regulatory mechanisms.

Hypoxia is well known to induce resistance to drugs and radiation in solid tumors and a number of studies have indicated a direct regulation of Twist1 by HIF-1α (32). Ding et al found that there was a positive correlation between HIF-1α and MDR1/P-gp expression in colon carcinoma (33). Additionally, HNE1-T3 cells that acquired paclitaxel-resistant were reported to show a high amplification of the Twist1 gene, decreased p53 and p21Waf1, but only a moderate alteration in MDR1/P-gp, which indicated that the Twist1-induced drug resistance results from interference with p53-related pathways (18). Furthermore, Cheng et al demonstrated that AKT2 is a downstream target of Twist1 and AKT2 is responsible for at least in part the Twist1-mediated paclitaxel resistance of breast cancer MCF-7 cells (20). Thus, the involvement of HIF-1α, p53 and AKT2 in the Twist1/MDR1-mediated cisplatin-resistant phenotype of cervical cancer will be investigated in our further studies.

In conclusion, this study provides the first evidence that Twist1 expression was significantly positively associated with MDR1/P-gp expression in human cervical cancer and that Twist1-mediated modulation of MDR1/P-gp expression plays an important role in the sensitization of cervical cancer cells to cisplatin treatment. Our results indicate a novel therapeutic strategy to overcome drug-resistance through inactivation of Twist1 expression in cervical cancer.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Greven K, Peterie D, Vermorken JB and Lanciano R: Current developments in the treatment of newly diagnosed cervical cancer. Hematol Oncol Clin North Am 13: 275-303, 1999.
3. Cornelio DB, Roesler R and Schwartsmann G: Emerging therapeutic agents for cervical cancer. Recent Pat Anticancer Drug Discov 4: 196-206, 2009.
4. Sardi JE, Boixadera MA and Sardi JJ: Neoadjuvant chemotherapy in cervical cancer: a new trend. Curr Opin Obstet Gynecol 17: 43-47, 2005.
5. Moore DH: Neoadjuvant chemotherapy for cervical cancer. Expert Opin Pharmacother 4: 859-867, 2003.
6. Tao X, Hu W, Ramirez PT and Kavanagh JJ: Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol 110: S67-S71, 2008.
7. Brabc V and Kasparkova J: Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat 5: 147-161, 2002.
8. Djen JY and Wei S: Clusterin and chemoresistance. Adv Cancer Res 105: 77-92, 2009.
9. Konishi I, Nanbu K and Mandai M, et al: Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-P in the tumor cells of cervical carcinoma. Gynecol Oncol 70: 365-371, 1998.
10. Britten RA, Liu D, Tessier A, Hutchison MJ and Murray D: ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 89: 453-457, 2000.
11. Takara K, Sakaeda T and Okumura K: An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12: 273-286, 2006.
12. Lage H: MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets 7: 813-821, 2006.
13. Xia Z, Zhu Z and Zhang L, et al: Specific reversal of MDR1/P-gp-dependent multidrug resistance by RNA interference in colon cancer cells. Oncol Rep 20: 1433-1439, 2008.
14. Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428, 2007.
15. Yang J, Mani SA and Donaher JL, *et al*; Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939, 2004.

16. Iseri OD, Kars MD, Arpaci F, Atalay C, Pak J and Gunduz U; Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 65: 40-45, 2011.

17. Yang AD, Fan F and Camp ER, *et al*; Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147-4153, 2006.

18. Wang X, Ling MT and Guan XY, *et al*; Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23: 474-482, 2004.

19. Li QQ, Xu JD and Wang WJ, *et al*; Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15: 2657-2665, 2009.

20. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD and Wang LH; Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67: 1979-1987, 2007.

21. Shibata K, Kajiyama H and Ino K, *et al*; Twist expression in patients with cervical cancer is associated with poor disease outcome. Ann Oncol 19: 81-85, 2008.

22. Kwok WK, Ling MT and Lee TW, *et al*; Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65: 5153-5162, 2005.

23. Martin TA, Goyal A, Watkins G and Jiang WG; Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 12: 488-496, 2005.

24. Yan-Qi Z, Xue-Yan G and Shuang H, *et al*; Expression and significance of TWIST basic helix-loop-helix protein over-expression in gastric cancer. Pathology 39: 470-475, 2007.

25. Puisieux A, Valsesia-Wittmann S and Ansieau S; A twist for survival and cancer progression. Br J Cancer 94: 13-17, 2006.

26. Chen T; Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev 62: 1257-1264, 2010.

27. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC and Colgan SP; Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394, 2002.

28. Sampath J, Sun D and Kidd VJ, *et al*; Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276: 39359-39367, 2001.

29. El-Osta A, Kantharidis P, Zalcberg JR and Wolfe AP; Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 22: 1844-1857, 2002.

30. Gomez-Martinez A, Garcia-Morales P and Carrato A, *et al*; Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. Mol Cancer Res 5: 641-653, 2007.

31. Chen Y, Tang Y, Wang MT, Zeng S and Nie D; Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res 67: 10361-10367, 2007.

32. Yang MH, Wu MZ and Chiou SH, *et al*; Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10: 295-305, 2008.

33. Ding Z, Yang L and Xie X, *et al*; Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J Cancer Res Clin Oncol 136: 1697-1707, 2010.